Fred Craves, Ph.D., will step down from Madrigal's Board of Directors in July 2025. This announcement comes from Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals (MDGL 16.35%) saw its shares rise by 15.2% by 11:05 a.m. ET on Wednesday.
The transcript of Madrigal Pharmaceuticals, Inc. (MDGL) earnings call for the fourth quarter of 2024 is available.
Madrigal (MDGL) reported a quarterly loss of $2.71 per share, which is better than the Zacks Consensus Estimate of a loss of $4.12. This is an improvement compared to a loss of $5.68 per share from the same period last year.
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical firm dedicated to creating new treatments for metabolic dysfunction-associated steatohepatitis (MASH), has announced its financial results for the fourth quarter and the entire year of 2024, along with key business updates.
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing new treatments for metabolic dysfunction-associated steatohepatitis (MASH), has announced encouraging two-year results from the open-label compensated MASH cirrhosis (F4c) group in the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom). Patients who received Rezdiffra showed significant decreases in liver stiffness, which is an indicator of fibrosis, as measured by vibration-controlled transient elastography (VCTE).
MDGL stock is increasing because it has announced fourth-quarter results that are better than anticipated, surpassing both earnings and revenue predictions. This success is mainly due to strong sales of Rezdiffra.
Madrigal Pharma's REZDIFFRA generated $100-$103 million in sales during the fourth quarter, showing a 61% increase, while only capturing 4% of the total addressable market, suggesting it could become a major success. Although there is potential competition from GLP-1 drugs and other MASH therapies, REZDIFFRA's unique combination use and its position as the first in the market help reduce these risks. Analysts expect sales to reach $515 million by 2025, supported by Medicare coverage, low market share, and its launch in Europe, making MDGL stock a strong buy.
Madrigal's stock dropped by 10% after the initial Q4 Rezdiffra sales numbers did not meet investors' expectations.
Madrigal Pharmaceuticals (MDGL) saw its shares drop by 13.3% at 11:11 a.m. ET on Monday.